Effectiveness of Canakinumab for First‐Line Steroid‐Free Treatment in Systemic‐Onset Juvenile Idiopathic Arthritis and Juvenile Still Disease

Key Points

• The aim is to evaluate the effectiveness of canakinumab as a steroid-free first-line treatment in systemic-onset juvenile idiopathic arthritis.
• Evaluated canakinumab for first-line treatment
• Focused on newly diagnosed systemic-onset juvenile idiopathic arthritis
• Monitored disease activity and flares after treatment discontinuation
• Canakinumab led to long-lasting, drug-free inactive disease in a significant number of patients
• A minority experienced disease flares after stopping treatment